<- Go Home
Clementia Pharmaceuticals Inc.
Clementia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase III MOVE trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada. As of April 17, 2019, Clementia Pharmaceuticals Inc. is as a subsidiary of 11188291 Canada Inc.
Market Cap
$1.0B
Volume
85.6K
Cash and Equivalents
$95.0M
EBITDA
-$59.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$26.73
52 Week Low
$8.10
Dividend
N/A
Price / Book Value
6.07
Price / Earnings
-14.83
Price / Tangible Book Value
6.13
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$59.4M
Return on Equity
37.97%
Return on Assets
-22.81
Cash and Short Term Investments
$170.0M
Debt
N/A
Equity
$164.4M
Revenue
N/A
Unlevered FCF
-$25.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium